{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:11:56Z","timestamp":1793664716118,"version":"4.5.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T00:00:00Z","timestamp":1524268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10928-018-9588-7","type":"journal-article","created":{"date-parts":[[2018,4,21]],"date-time":"2018-04-21T10:39:19Z","timestamp":1524307159000},"page":"593-605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%"],"prefix":"10.1007","volume":"45","author":[{"given":"Matthew L.","family":"Fidler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abayomi","family":"Ogundele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Covert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Sarangapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,21]]},"reference":[{"issue":"4","key":"9588_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1517\/17425255.4.4.453","volume":"4","author":"MB Abelson","year":"2008","unstructured":"Abelson MB, Gomes PJ (2008) Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol 4(4):453\u2013461","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"9588_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2500\/ar.2016.7.0158","volume":"7","author":"W Carr","year":"2016","unstructured":"Carr W, Schaeffer J, Donnenfeld E (2016) Treating allergic conjunctivitis: a once-daily medication that provides 24-hour symptom relief. Allergy Rhinol (Providence) 7(2):107\u2013114","journal-title":"Allergy Rhinol (Providence)"},{"issue":"5","key":"9588_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/ACI.0b013e32834a9676","volume":"11","author":"N Rosario","year":"2011","unstructured":"Rosario N, Bielory L (2011) Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 11(5):471\u2013476","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"9588_CR4","first-page":"485","volume":"18","author":"S Butrus","year":"2005","unstructured":"Butrus S, Portela R (2005) Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 18(4):485\u2013492","journal-title":"Ophthalmol Clin North Am"},{"issue":"12","key":"9588_CR5","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/j.1365-2222.2012.04025.x","volume":"42","author":"J Maspero","year":"2012","unstructured":"Maspero J, Lee BW, Katelaris CH et al (2012) Quality of life and control of allergic rhinitis in patients from regions beyond western Europe and the United States. Clin Exp Allergy 42(12):1684\u20131696","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"9588_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1076\/opep.11.1.17.26437","volume":"11","author":"AD Pitt","year":"2004","unstructured":"Pitt AD, Smith AF, Lindsell L et al (2004) Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 11(1):17\u201333","journal-title":"Ophthalmic Epidemiol"},{"issue":"4","key":"9588_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/09286580590967781","volume":"12","author":"AF Smith","year":"2005","unstructured":"Smith AF, Pitt AD, Rodruiguez AE et al (2005) The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 12(4):233\u2013242","journal-title":"Ophthalmic Epidemiol"},{"issue":"3","key":"9588_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2500\/aap.2014.35.3750","volume":"35","author":"L Bielory","year":"2014","unstructured":"Bielory L, Skoner DP, Blaiss MS et al (2014) Ocular and nasal allergy symptom burden in America: the allergies, immunotherapy, and rhinoconjunctivitiS (AIRS) surveys. Allergy Asthma Proc 35(3):211\u2013218","journal-title":"Allergy Asthma Proc"},{"issue":"7","key":"9588_CR9","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1185\/03007990903021968","volume":"25","author":"DE Stull","year":"2009","unstructured":"Stull DE, Schaefer M, Crespi S et al (2009) Relative strength of relationships of nasal congestion and ocular symptoms with sleep, mood and productivity. Curr Med Res Opin 25(7):1785\u20131792","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"9588_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3111\/13696998.2011.576039","volume":"14","author":"JC Virchow","year":"2011","unstructured":"Virchow JC, Kay S, Demoly P et al (2011) Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients\u2013an observational, cross sectional study in four countries in Europe. J Med Econ 14(3):305\u2013314","journal-title":"J Med Econ"},{"issue":"16","key":"9588_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jama.2013.280318","volume":"310","author":"AA Azari","year":"2013","unstructured":"Azari AA, Barney NP (2013) Conjunctivitis: a systematic review of diagnosis and treatment. JAMA 310(16):1721\u20131729","journal-title":"JAMA"},{"issue":"6","key":"9588_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1081-1206(10)63063-3","volume":"79","author":"JM Yanni","year":"1997","unstructured":"Yanni JM, Miller ST, Gamache DA et al (1997) Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 79(6):541\u2013545","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9588_CR13","unstructured":"Drugs@FDA: FDA Approved Drug Products [April 4, 2017]. \n                    https:\/\/www.accessdata.fda.gov"},{"key":"9588_CR14","unstructured":"PAZEO [Prescribing Information]: Fort Worth, Texas: Alcon Laboratories Inc; 2015"},{"issue":"10","key":"9588_CR15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ICO.0000000000000562","volume":"34","author":"E McLaurin","year":"2015","unstructured":"McLaurin E, Narvekar A, Gomes P et al (2015) Phase 3 randomized double-masked study of efficacy and safety of once-daily 0.77% olopatadine hydrochloride ophthalmic solution in subjects with allergic conjunctivitis using the conjunctival allergen challenge model. Cornea 34(10):1245\u20131251","journal-title":"Cornea"},{"key":"9588_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.2147\/OPTH.S83263","volume":"9","author":"G Torkildsen","year":"2015","unstructured":"Torkildsen G, Narvekar A, Bergmann M (2015) Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model. Clin Ophthalmol 9:1703\u20131713","journal-title":"Clin Ophthalmol"},{"key":"9588_CR17","unstructured":"Internal Data. Alcon Laboratories Inc"},{"issue":"1","key":"9588_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/archopht.1990.01070030090035","volume":"108","author":"MB Abelson","year":"1990","unstructured":"Abelson MB, Chambers WA, Smith LM (1990) Conjunctival allergen challenge: a clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 108(1):84\u201388","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"9588_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10928-008-9098-0","volume":"35","author":"MC Kjellsson","year":"2008","unstructured":"Kjellsson MC, Zingmark PH, Jonsson EN et al (2008) Comparison of proportional and differential odds models for mixed-effects analysis of categorical data. J Pharmacokinet Pharmacodyn 35(5):483\u2013501","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"9588_CR20","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8):1296\u20131310","journal-title":"Clin Ther"},{"key":"9588_CR21","doi-asserted-by":"crossref","unstructured":"Richter A, Anton SF, Koch P, et al (2003). The impact of reducing dose frequency on health outcomes. Clin Ther 25(8):2307\u20132335; discussion 6","DOI":"10.1016\/S0149-2918(03)80222-9"},{"key":"9588_CR22","doi-asserted-by":"crossref","unstructured":"Carr W, et al (2016). Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief. allergy Rhinol 7:107\u2013114","DOI":"10.2500\/ar.2016.7.0158"},{"issue":"3","key":"9588_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10453-008-9091-5","volume":"24","author":"H Ribeiro","year":"2008","unstructured":"Ribeiro H, Oliveira M, Abreu I (2008) Intradiurnal variation of allergenic pollen in the city of Porto (Portugal). Aerobiologia 24(3):173","journal-title":"Aerobiologia"},{"issue":"4","key":"9588_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1089\/jop.2014.0140","volume":"31","author":"GR Iyer","year":"2015","unstructured":"Iyer GR, Cason MM, Womble SW et al (2015) Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits. J Ocul Pharmacol Ther 31(4):204\u2013210","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-018-9588-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T20:02:31Z","timestamp":1555790551000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-018-9588-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,21]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["9588"],"URL":"https:\/\/doi.org\/10.1007\/s10928-018-9588-7","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,21]]},"assertion":[{"value":"7 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}